Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Tuberculosis: what we don't know can, and does, hurt us.

Russell DG, Barry CE 3rd, Flynn JL.

Science. 2010 May 14;328(5980):852-6. doi: 10.1126/science.1184784. Review.

2.

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.

Dietrich J, Doherty TM.

APMIS. 2009 May;117(5-6):440-57. doi: 10.1111/j.1600-0463.2009.02458.x. Review.

PMID:
19400867
3.

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Kiran D, Podell BK, Chambers M, Basaraba RJ.

Semin Immunopathol. 2016 Mar;38(2):167-83. doi: 10.1007/s00281-015-0537-x. Epub 2015 Oct 28. Review.

5.

Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.

Lin MY, Ottenhoff TH.

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):15-29. Review.

PMID:
18393920
6.

Mycobacterium tuberculosis metabolism.

Warner DF.

Cold Spring Harb Perspect Med. 2014 Dec 11;5(4). pii: a021121. doi: 10.1101/cshperspect.a021121. Review.

7.

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.

Lin MY, Geluk A, Smith SG, Stewart AL, Friggen AH, Franken KL, Verduyn MJ, van Meijgaarden KE, Voskuil MI, Dockrell HM, Huygen K, Ottenhoff TH, Klein MR.

Infect Immun. 2007 Jul;75(7):3523-30. Epub 2007 May 14.

8.

The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.

Zárate-Bladés CR, Silva CL, Passos GA.

Clin Dev Immunol. 2011;2011:192630. doi: 10.1155/2011/192630. Epub 2010 Dec 20. Review.

9.

[Molecular medicine and treatment of tuberculosis].

Perel'man MI, Khomiakov IuN, Kiselev VI, Severin ES, Pal'tsev MA.

Probl Tuberk. 2001;(5):5-7. Russian. No abstract available.

PMID:
11588966
10.

Vaccination against tuberculosis: how can we better BCG?

Pitt JM, Blankley S, McShane H, O'Garra A.

Microb Pathog. 2013 May;58:2-16. doi: 10.1016/j.micpath.2012.12.002. Epub 2012 Dec 17. Review.

PMID:
23257069
11.

Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains.

Kremer K, van-der-Werf MJ, Au BK, Anh DD, Kam KM, van-Doorn HR, Borgdorff MW, van-Soolingen D.

Emerg Infect Dis. 2009 Feb;15(2):335-9.

12.

Cytokine and lipid mediator networks in tuberculosis.

Mayer-Barber KD, Sher A.

Immunol Rev. 2015 Mar;264(1):264-75. doi: 10.1111/imr.12249. Review.

13.

Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection.

Sukumar N, Tan S, Aldridge BB, Russell DG.

PLoS Pathog. 2014 Sep 18;10(9):e1004394. doi: 10.1371/journal.ppat.1004394. eCollection 2014 Sep.

14.

The challenge of new drug discovery for tuberculosis.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K.

Nature. 2011 Jan 27;469(7331):483-90. doi: 10.1038/nature09657. Review.

PMID:
21270886
15.

Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice.

Nandakumar S, Kannanganat S, Posey JE, Amara RR, Sable SB.

PLoS One. 2014 Nov 24;9(11):e113951. doi: 10.1371/journal.pone.0113951. eCollection 2014.

16.
17.

Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Shang S, Shanley CA, Caraway ML, Orme EA, Henao-Tamayo M, Hascall-Dove L, Ackart D, Orme IM, Ordway DJ, Basaraba RJ.

Vaccine. 2012 Feb 21;30(9):1572-82. doi: 10.1016/j.vaccine.2011.12.114. Epub 2012 Jan 11.

18.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
19.

Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Orme IM.

Future Microbiol. 2011 Feb;6(2):161-77. doi: 10.2217/fmb.10.168. Review.

20.

Supplemental Content

Support Center